250 related articles for article (PubMed ID: 34698447)
21. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I
Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
23. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
24. Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis.
Taioli E; Wolf A; Alpert N; Rosenthal D; Flores R
J Surg Oncol; 2023 Jul; 128(1):134-141. PubMed ID: 36932968
[TBL] [Abstract][Full Text] [Related]
25. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Christoph DC; Asuncion BR; Mascaux C; Tran C; Lu X; Wynes MW; Gauler TC; Wohlschlaeger J; Theegarten D; Neumann V; Hepp R; Welter S; Stamatis G; Tannapfel A; Schuler M; Eberhardt WE; Hirsch FR
J Thorac Oncol; 2012 Sep; 7(9):1440-8. PubMed ID: 22895141
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
Christoph DC; Eberhardt WE
Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
[TBL] [Abstract][Full Text] [Related]
27. What's Current and What's New in Mesothelioma?
Leal JL; Hoang W; Xue J; Dunne B; John T; Harden S
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):771-780. PubMed ID: 36155156
[TBL] [Abstract][Full Text] [Related]
28. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed in malignant pleural mesothelioma and the clinical outcome.
Knuuttila A; Salomaa ER; Saikkonen S; Hurme S; Salo J
Clin Respir J; 2012 Apr; 6(2):96-103. PubMed ID: 21651743
[TBL] [Abstract][Full Text] [Related]
30. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
31. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
32. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).
Raynaud C; Greillier L; Mazieres J; Monnet I; Mastroianni B; Robinet G; Fraboulet G; Dixmier A; Berard H; Lamy R; Letreut J; Lena H; Oliviero G; Botta S; Vergnenegre A; Borget I; Chouaid C
BMC Cancer; 2015 Nov; 15():857. PubMed ID: 26546402
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
34. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
35. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
36. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
37. Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
Horio D; Minami T; Kitai H; Ishigaki H; Higashiguchi Y; Kondo N; Hirota S; Kitajima K; Nakajima Y; Koda Y; Fujimoto E; Negi Y; Niki M; Kanemura S; Shibata E; Mikami K; Takahashi R; Yokoi T; Kuribayashi K; Kijima T
Cancer Sci; 2020 Aug; 111(8):2895-2906. PubMed ID: 32530527
[TBL] [Abstract][Full Text] [Related]
38. [Progress in treatment for malignant pleural mesothelioma].
Wang YY; He YL; Chi YJ; Zhai XY; An TT; Li JJ; Zhuo ML; Zhao J; Wang ZP
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):111-115. PubMed ID: 35000316
[TBL] [Abstract][Full Text] [Related]
39. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
[TBL] [Abstract][Full Text] [Related]
40. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]